Rationale: Eradication and suppression of Pseudomonas aeruginosa is a key priority in national
guidelines for bronchiectasis and is a major focus of drug development and clinical trials…

Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent
exacerbations in many patients. There have been no previous international guidelines. The …

Rationale: There are no risk stratification tools for morbidity and mortality in bronchiectasis.
Identifying patients at risk of exacerbations, hospital admissions, and mortality is vital for …

Rationale: Testing for underlying etiology is a key part of bronchiectasis management, but it
is unclear whether the same extent of testing is required across the spectrum of disease …

Bronchiectasis is a heterogeneous disease. This study aimed at identifying discrete groups
of patients with different clinical and biological characteristics and long-term outcomes. This …

Background Patients with bronchiectasis often have concurrent comorbidities, but the nature,
prevalence, and impact of these comorbidities on disease severity and outcome are poorly …

Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical
predictors and outcomes of patients with frequently exacerbating disease are not well …

Background Bronchiectasis is a common but neglected chronic lung disease. Most
epidemiological data are limited to cohorts from Europe and the USA, with few data from low-income …

Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients
but it is not known whether it is associated with worse clinical outcomes independent of …

Background The hallmark of non-cystic fibrosis bronchiectasis is recurrent bronchial infection,
yet there are significant gaps in our understanding of pathogen persistence, resistance …